# 5-MeO-MiPT

5-MeO-MiPT is a psychedelic and hallucinogen of the tryptamine family. It used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT$_{2A}$ receptor.
5-MeO-MiPT was first described in the scientific literature by Alexander Shulgin and colleagues in 1985.

## Chemistry

5-MeO-MiPT is in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of the psychedelic, 5-MeO-DMT. The full name of the chemical is 5-methoxy-N-methyl-N-isopropyltryptamine.
5-MeO-MiPT causes the ehrlich reagent to turn purple then fade to faint blue. It causes the marquis reagent to go yellow through to black.

## Effects

This is an analogue of the more popular drug 5-MeO-DiPT (nicknamed "foxy methoxy") and has the nickname "moxy". Some users report the tactile effects of 5-MeO-DiPT without some of the unwanted side effects. At higher doses it becomes much more psychedelic sometimes being compared to 5-MeO-DMT. But at doses of 4-10 milligrams users find 5-MeO-MiPT to be a very euphoric and tactile chemical. Its energetic effects can be very strong at high doses, increasing normal heart rate considerably. Sounds can be amplified in perception to a point where synesthetic effects ("touching or/and tasting sounds") occur.

## Pharmacology
### Pharmacodynamics

5-MeO-MiPT activities :
| Target | Affinity (K$_i$, nM) |
| 5-HT$_{1A}$ | 12–143 (K$_i$) 610–>10,000 (EC$_{50}$Tooltip Half-maximal effective concentration) |
| 5-HT$_{1B}$ | 303 |
| 5-HT$_{1D}$ | 23 |
| 5-HT$_{1E}$ | 3,496 |
| 5-HT$_{1F}$ | ND |
| 5-HT$_{2A}$ | 113–449 (K$_i$) 5.9–566 (EC$_{50}$) 82–101% (E$_{max}$Tooltip maximal efficacy) |
| 5-HT$_{2B}$ | 59 (K$_i$) 1,500 (EC$_{50}$) 12% (E$_{max}$) |
| 5-HT$_{2C}$ | 790–2,186 (K$_i$) 179 (EC$_{50}$) |
| 5-HT$_3$ | >10,000 |
| 5-HT$_4$ | ND |
| 5-HT$_{5A}$ | 953 |
| 5-HT$_6$ | 130 |
| 5-HT$_7$ | 20 |
| α$_{1A}$ | >12,000 |
| α$_{1B}$ | >10,000 |
| α$_{2A}$ | 175–5,300 |
| α$_{2B}$ | 1,693 |
| α$_{2C}$ | 637 |
| β$_1$–β$_2$ | >10,000 |
| D$_1$ | >25,000 |
| D$_2$ | >25,000 |
| D$_3$ | 2,470–>25,000 |
| D$_4$ | 6,331 |
| D$_5$ | >10,000 |
| H$_1$ | 3,900–4,819 |
| H$_2$–H$_4$ | >10,000 |
| I$_1$ | 879 |
| TAAR$_1$ | >15,000 (rat/mouse) |
| σ$_1$ | >10,000 |
| σ$_2$ | 918 |
| SERTTooltip Serotonin transporter | 3,300–6,409 (K$_i$) 2,680–29,768 (IC$_{50}$Tooltip half-maximal inhibitory concentration) >100,000 (EC$_{50}$) |
| NETTooltip Norepinephrine transporter | >22,000 (K$_i$) 84,000 (IC$_{50}$) >100,000 (EC$_{50}$) |
| DATTooltip Dopamine transporter | >26,000 (K$_i$) >100,000 (IC$_{50}$) >100,000 (EC$_{50}$) |
| Notes: The smaller the value, the more avidly the drug binds to the site. Refs: ||
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-MiPT is thought to result primarily from serotonin 5-HT$_{2A}$ receptor agonism, although additional mechanisms of action such as inhibition of monoamine oxidase (MAO) might also be involved. In addition to the serotonin 5-HT$_{2A}$ receptor, 5-MeO-MiPT also potently binds to and/or activates other serotonin receptors, such as the serotonin 5-HT$_{1A}$, 5-HT$_{2B}$, and 5-HT$_{2C}$ receptors.
In addition to the serotonin receptors, 5-MeO-MiPT has also been found to show significant affinity to the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby acting as a moderately potent serotonin–norepinephrine reuptake inhibitor (SNRI). These mechanisms might help explain anecdotal reports of antidepressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the serotonin 5-HT$_{1A}$ receptor agonist buspirone is prescribed primarily for treatment of anxiety. However, subsequent research contradicted the preceding findings and found that 5-MeO-MiPT did not significantly bind to or inhibit the human monoamine transporters. The drug is also inactive as a monoamine releasing agent.

## Dosage

Based on Shulgin's personal experience, dosage for an adult male of approximately 6' and 200lbs:
DOSAGE: 4 - 6 mg, orally; 12 - 20 mg, smoked
DURATION : 4 - 6 hrs

## Reagent results

Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from protestkit.
| 5-MeO-MiPT | Marquis | Mecke | Mandelin | Liebermann | Ehrlich | Hofmann | Simon’s |
| Freebase | Orange to brown | Orange red | Deep greenish brown | Unknown | Purple | No reaction | No reaction |
| HCl | Orange to brown | Red to brown | Greenish brown | Brown | Violet to purple | Green | Unknown |

## Dangers

The toxicity of 5-MeO-MiPT is not known. There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.

## Legal status
### Canada

5-MeO-MiPT is not scheduled in Canada.

### China

As of October 2015 5-MeO-MiPT is a controlled substance in China.

### Finland

Scheduled in government decree on psychoactive substances banned from the consumer market.

### Luxembourg

In Luxembourg, 5-MeO-MiPT is not cited in the list of prohibited substances. Therefore, it is still a legal substance.

### United Kingdom

5-MeO-MiPT is a Class A drug in the United Kingdom as are most ethers of ring-hydroxy tryptamines.

### United States

5-MeO-MiPT is unscheduled at the federal level in the United States, but it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession with intent to consume could be prosecuted under the Federal Analog Act.

#### Florida

"5-Methoxy-N-methyl-N-isopropyltryptamine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in the state of Florida.

## Research

5-MeO-MiPT, under the developmental code name MSD-001, is being developed for potential medical use. As of September 2024, it is in phase 1 clinical trials in healthy individuals in the United States and the European Union. It is being developed by Mindstate Design Labs. The drug was selected for development via artificial intelligence (AI)-assisted processing of 70,000 online trip reports that aimed to identify a psychedelic with unique subjective effects deemed promising for pharmaceutical development.